Active Biotech Secures US Patent for Tasquinimod Formulation, Extending Market Exclusivity to 2042
Key Insights
Active Biotech announced that the US Patent and Trademark Office (search) will grant patent number 12,485,095 for a pharmaceutical formulation of tasquinimod on December 2, 2025.
The patent provides market exclusivity protection until 2042 and relates to a formulation with high oral bioavailability for the immunomodulatory drug.
Tasquinimod has received FDA orphan drug status for treating myelofibrosis (search) and multiple myeloma (search), with Active Biotech focusing development on rare blood cancers.
Active Biotech AB announced on November 25, 2025, that the US Patent and Trademark Office (search) (USPTO) has issued notification that the company's patent application for a pharmaceutical formulation containing tasquinimod will be granted on December 2, 2025, under patent number 12,485,095. The patent will provide protection and market exclusivity until 2042.
Strategic Intellectual Property Enhancement
"This patent marks an important step in our strategy to optimize the global multi-layer protection for tasquinimod," said Active Biotech's CEO Helén Tuvesson. The patent application specifically relates to a pharmaceutical formulation of tasquinimod with high oral bioavailability, addressing a critical aspect of drug delivery for this immunomodulatory compound.
The newly granted patent adds to tasquinimod's existing intellectual property portfolio, which includes multiple patents and patent applications primarily covering medical use in relevant indications. The drug has already been granted orphan drug status by the FDA for the treatment of myelofibrosis (search) and multiple myeloma (search).
Company Focus and Development Pipeline
Active Biotech AB operates as a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications with high unmet medical needs and significant commercial potential. The company maintains three projects in its portfolio, including tasquinimod and laquinimod, which are small molecule immunomodulators.
The company is primarily focused on developing tasquinimod for myelofibrosis (search), a rare blood cancer, and has initiated clinical proof-of-concept studies in this area. Beyond tasquinimod, Active Biotech's pipeline includes laquinimod for non-infectious uveitis (search) and naptumomab for advanced solid tumors, developed in partnership with NeoTX Therapeutics (search).
Market Position and Therapeutic Potential
Tasquinimod is being developed for hematological malignancies and has demonstrated therapeutic potential in multiple myeloma (search) and myelofibrosis (search). The patent grant is expected to strengthen Active Biotech's position in the biotechnology industry, particularly in oncology and immunology sectors.
The company currently maintains a market capitalization of SEK 171.3 million with an average trading volume of 6,555,902 shares. The patent protection extending to 2042 provides long-term market exclusivity that may enhance the company's competitive positioning and commercial potential for tasquinimod across its targeted indications.